Pregnant women with hepatitis c get new hope from antiviral drug

NCT ID NCT05140941

First seen Feb 04, 2026 · Last updated May 12, 2026 · Updated 12 times

Summary

This study is testing a 12-week course of the hepatitis C drug Sofosbuvir/Velpatasvir in about 100 pregnant women. The goal is to see if the treatment cures the infection and whether it affects the timing of delivery. Mothers are followed for 12 weeks after treatment, and babies are monitored for one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Marshall University

    Huntington, West Virginia, 25755, United States

  • The Christ Hospital

    Cincinnati, Ohio, 45219, United States

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • Toronto General Hospital, University Health Network

    Toronto, Ontario, M5G 2C4, Canada

  • University Health Toronto, St Michaels Hospital

    Toronto, Ontario, M5B 1W8, Canada

  • University of Pittsburgh, Magee Womens Hospital

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Utah

    Salt Lake City, Utah, 84132, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Victoria Hospital, London Health Sciences Center

    London, Ontario, N6A 5W9, Canada

Conditions

Explore the condition pages connected to this study.